Advicenne SA

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

Div Yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

72.09%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.

URL

https://advicenne.com/

IPO date

Dec 06, 2017

Employees

Domiciled in

Incorporated in

Valuation

No data to show